SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Active, not recruiting · NCT03161431 · Registry updated 2025-12-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 | 2025-12-23 | NCT03161431 |
8 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| M.D. Anderson Cancer Center | 1145 |
| Massachusetts General Hospital | 758 |
| Mayo Clinic | 970 |
| National Cancer Institute (NCI) | 3015 |
| Syntrix Biosystems, Inc. | 9 |
| University of Miami | 277 |
| University of Rochester | 189 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |
| Mayo Clinic | Rochester | United States | 664 |
| MD Anderson | Houston | United States | 56 |
| University of Miami | Miami | United States | 327 |
| Wilmot Cancer Institute - University of Rochester | Rochester | United States | 1 |